Key Takeaways
- Kratom (Mitragyna speciosa) is a Southeast‑Asian plant sold in many U.S. gas stations, vitamin stores, and smoke shops as capsules, powders, teas, gummies, or smokable forms.
- At the federal level it remains legal and is not FDA‑approved; the agency warns of safety concerns and potential for addiction or psychosis.
- Effects are dose‑dependent: low doses act as a stimulant, high doses as a sedative.
- As of mid‑2025, at least eight states have fully banned kratom (Alabama, Arkansas, Indiana, Louisiana, Vermont, Wisconsin, Rhode Island—though RI later switched to regulation—and Tennessee, with a ban effective July 1 2026; Kentucky’s ban starts in 2027).
- Mississippi permits kratom sales only to adults 21 +, requires products to be kept behind the counter, and mandates clear labeling with manufacturer info. Nonetheless, 24 cities and 11 counties within the state have enacted local bans.
- The DEA is reviewing a proposal to schedule 7‑hydroxymitragynine (7‑OH), a potent kratom byproduct, as a Schedule I substance; the FDA has already cracked down on 7‑OH products.
- High‑profile cases, such as the arrest of Memphis Grizzlies player Brandon Clarke for possessing >230 g of kratom in Arkansas and the ongoing investigation into his death, have heightened public scrutiny.
- Advocacy groups like the American Kratom Association support FDA regulation to ensure product purity and safety, while also endorsing age limits to keep minors from accessing kratom.
Kratom’s legal landscape in the United States is a patchwork of federal permissiveness, state‑level bans, and local restrictions. Although the substance is not scheduled under the Controlled Substances Act, the U.S. Food and Drug Administration (FDA) has repeatedly warned that kratom products may be unsafe, citing risks of addiction, psychosis, and adverse interactions when combined with other drugs. The Drug Enforcement Administration (DEA) is currently evaluating whether to classify 7‑hydroxymitragynine (7‑OH)—a concentrated alkaloid derived from kratom—as a Schedule I illicit substance, a move that would dramatically tighten federal control.
In Mississippi, state law allows kratom to be sold only to individuals aged 21 and older, requires retailers to keep the products behind the counter, and obliges labels to display the manufacturer’s name and contact information. Despite these safeguards, a substantial number of municipalities have opted for outright prohibition. According to a 2025 list compiled by the online vendor Kratom Country, kratom is banned in the following Mississippi counties: Alcorn, Calhoun, Itawamba, Lowndes, Monroe, Noxubee, Pearl River, Prentiss, Tippah, Tishomingo, and Union. The same source lists numerous cities where kratom is illegal, including Belmont, Blue Mountain, Booneville, Bruce, Burnsville, Caledonia, Calhoun City, Columbus, Corinth, Derma, Fulton, Guntown, Iuka, Mantachie, Marietta, New Albany, Okolona, Oxford, Pontotoc, Ripley, Saltillo, Senatobia, Tishomingo, and Vardaman.
The debate over kratom intensified after several high‑profile incidents. In early 2026, Memphis Grizzlies forward Brandon Clarke was arrested in Arkansas on charges that included trafficking a controlled substance after authorities found more than 230 grams of kratom in his possession. Clarke’s subsequent death is under investigation as a possible overdose, though the exact substances involved have not been disclosed. Similar concerns have arisen elsewhere; Los Angeles County issued a public health warning in 2025 after three overdose deaths were linked to kratom products, and the substance has been noted as a contributing factor in the death of chess grandmaster Daniel Naroditsky, typically when combined with other drugs.
Public figures have also shaped perceptions. Podcast host Joe Rogan frequently discusses his personal kratom use, reaching millions of listeners and contributing to the herb’s growing popularity despite mounting regulatory pressure. Advocacy organizations such as the American Kratom Association argue for continued access, emphasizing that kratom has been used for centuries in Southeast Asia as a stimulant and analgesic. The group urges the FDA to implement standards that ensure product purity and potency, and it supports age‑restriction policies to prevent under‑age use.
Scientifically, kratom’s pharmacology is complex. Low doses tend to produce stimulant‑like effects—increased energy, alertness, and sociability—while higher doses can induce sedation, analgesia, and euphoria. These effects stem from the alkaloids mitragynine and 7‑hydroxymitragynine interacting with opioid receptors, though the plant also influences other neurotransmitter systems. Because product potency varies widely—especially with “fast‑food” formulations like gummies, teas, and smokable versions—users may unintentionally consume doses that lead to adverse outcomes, including dependence, withdrawal symptoms, or severe psychiatric reactions.
In sum, while kratom remains federally unregulated and legal in many jurisdictions, a growing number of states and localities are moving to restrict or ban its sale due to safety concerns, addiction potential, and high‑profile cases linking the substance to harmful health events. Mississippi exemplifies this tension: state law permits regulated adult sales, yet numerous cities and counties have enacted local bans, reflecting ongoing community unease. The forthcoming DEA decision on 7‑OH and continued FDA scrutiny will likely shape the future availability and legal status of kratom across the country.